With over 33,000 employees worldwide, production plants in 13 countries and annual sales of over $22 billion worldwide, Eli Lilly and Company is one of the largest pharmaceutical companies in the world. It was founded in Indianapolis in 1876 by the pharmacologist, officer and entrepreneur Eli Lilly.
P/E ratio for Eli Lilly (LLY)
P/E ratio as of June 2025 (TTM): 66.3
According to Eli Lilly's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 66.3127. At the end of 2024 the company had a P/E ratio of 65.6.
P/E ratio history for Eli Lilly from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 65.6 | -36.46% |
| 2023 | 103 | 89.32% |
| 2022 | 54.5 | 16.69% |
| 2021 | 46.7 | 79.14% |
| 2020 | 26.1 | 70.08% |
| 2019 | 15.3 | -58.87% |
| 2018 | 37.3 | -111.57% |
| 2017 | -322 | -1186.75% |
| 2016 | 29.6 | -23.6% |
| 2015 | 38.8 | 20.27% |
| 2014 | 32.3 | 163.09% |
| 2013 | 12.3 | -9.49% |
| 2012 | 13.5 | 27.1% |
| 2011 | 10.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Bristol-Myers Squibb BMY | 18.6 | -72.01% | 🇺🇸 USA |
 Merck MRK | 11.8 | -82.14% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 17.3 | -73.87% | 🇺🇸 USA |
 Pfizer PFE | 17.7 | -73.38% | 🇺🇸 USA |
 Sanofi SNY | 17.4 | -73.73% | 🇫🇷 France |
 GlaxoSmithKline GSK | 26.2 | -60.49% | 🇬🇧 UK |
 AbbVie ABBV | 81.1 | 22.22% | 🇺🇸 USA |
 Amgen AMGN | 26.7 | -59.71% | 🇺🇸 USA |
 Novartis NVS | 18.6 | -71.99% | 🇨🇭 Switzerland |
 AstraZeneca AZN | 29.7 | -55.20% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.